Showing 3041-3050 of 3315 results for "".
- USRetina Announces Changes to Senior Management Teamhttps://modernod.com/news/usretina-announces-changes-to-senior-management-team/2477256/USRetina, an independent provider of technology and services specific to retina practices, announced that it has expanded its leadership team with the appointment of a new executive team. The change reflects a strategic approach to long-term value and growth for the organization, according to the
- Ocuphire Pharma Announces In-License of Phase 2 Oral Small Molecule Drug Candidate for DR and DME from Apexian Pharmaceuticalshttps://modernod.com/news/ocuphire-pharma-announces-in-license-of-phase-2-oral-small-molecule-drug-candidate-for-dr-and-dme-from-apexian-pharmaceuticals/2477254/Ocuphire Pharma announced that it has entered into an agreement with Apexian Pharmaceuticals, granting Ocuphire an exclusive worldwide sublicense to Apexian’s Ref-1 Inhibitor program, including its lead drug candidate APX3330, for all ophthalmic and diabetic indications. APX3330 is a first
- AOA Receives Department of Justice Approval to Expand Group Purchasing Activities for Its AOAExcel Membershttps://modernod.com/news/aoa-receives-department-of-justice-approval-to-expand-group-purchasing-activities-for-its-aoaexcel-members/2477244/The Department of Justice (DOJ) announced January 15 that it will not challenge a proposal by the American Optometric Association to expand its group purchasing organization’s (GPO) activities to include the purchase of optometric products for resale to consumers, specifically eyeglass lenses, fr
- The Vision Council Notes That U.S.-China Trade Agreement Will Result in Tariff Reductions on Certain Optical Productshttps://modernod.com/news/the-vision-council-notes-that-u-s-china-trade-agreement-will-result-in-tariff-reductions-on-certain-optical-products/2477239/The trade deal between the US and China that requires structural reforms to China’s economic and trade regimes will also lead to a modification of a portion of the existing Section 301 China tariffs, according to The Vision Council, as
- IrisVision and Samsung Announce Partnership to Roll Out Vision Correction Software Platformhttps://modernod.com/news/irisvision-and-samsung-announce-partnership-to-roll-out-vision-correction-software-platform/2477229/Samsung Electronics and IrisVision announced a strategic partnership to roll out IrisVision’s technology worldwide. IrisVision’s vision correction software platform utilizes the power of Samsung’s industry leading Galaxy smartphones and XR devices and mobile AI platform to enable people
- Gemini Therapeutics Enrolls First Patient in Phase 1 Study of GEM103 for Dry AMDhttps://modernod.com/news/gemini-therapeutics-enrolls-first-patient-in-phase-1-study-of-gem103-for-dry-amd/2477214/Gemini Therapeutics announced it has initiated enrollment in its phase 1 study of GEM103, a recombinant, native Complement Factor H (CFH) for the treatment of dry age-related macular degeneration. AMD is the leading cause of irreversible blindness in the western world—affecting millions of
- Tarsus Pharmaceuticals Raises $60 Million for Demodex Blepharitis Drug Trialhttps://modernod.com/news/tarsus-pharmaceuticals-raises-60-million-for-demodex-blepharitis-drug-trial/2477213/Tarsus Pharmaceuticals announced the completion of $60 million in Series B financing. Tarsus will use the funds to initiate a phase 2b/3 trial in the United States of their lead product TP-03 for Demodex blepharitis and fuel phase 1 and 2 development of other clinical programs. An estimate
- Aura Biosciences Appoints George Golumbeski, PhD, as Chairman of the Board of Directorshttps://modernod.com/news/aura-biosciences-appoints-george-golumbeski-phd-as-chairman-of-the-board-of-directors/2477212/Aura Biosciences announced the appointment of George Golumbeski, PhD, as Chairman of its Board of Directors. Dr. Golumbeski is a biopharmaceutical business leader with over 25 years of experience in the biotechnology industry. “George’s extensive experience will be invaluable to Aura as we
- Eyevensys Closes $30M Series B Financinghttps://modernod.com/news/eyevensys-closes-30m-series-b-financing/2477210/Eyevensys announced that it has completed a $30 million Series B financing. The company will use the funds to continue the development of its clinical lead candidate EYS606 for the treatment of chronic noninfectious uveitis (NIU), including the launch of its Electro Study. This phase 2 trial, to
- CooperVision Launches First Best Practices Scholarship Programhttps://modernod.com/news/coopervision-launches-first-best-practices-scholarship-program/2477193/To enable future eye care professionals to learn from some of the best in optometry, CooperVision announced the launch of its first “Best Practices Scholarship Program.” The scholarship—offered to third-year optometry students—is an expansion of the company’s annual Best Practices ini